|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000167552 |
Summary for TUBA1A |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000167552 | Gene symbol | TUBA1A |
| Gene name | tubulin alpha 1a | |
| HGNC | 20766 | |
| Entrez ID | 7846 | |
| Gene type | protein_coding | |
| Synonyms | TUBA1A|TUBA3|B-ALPHA-1|FLJ25113 | |
| UniProtAcc | Q71U36 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| ENSG00000167552 | TUBA1A | DB00518 | Albendazole | SmallMoleculeDrug |
| ENSG00000167552 | TUBA1A | DB00570 | Vinblastine | SmallMoleculeDrug |
| ENSG00000167552 | TUBA1A | DB00643 | Mebendazole | SmallMoleculeDrug |
| ENSG00000167552 | TUBA1A | DB01873 | Epothilone D | SmallMoleculeDrug |
| ENSG00000167552 | TUBA1A | DB03010 | Patupilone | SmallMoleculeDrug |
| ENSG00000167552 | TUBA1A | DB05147 | CYT997 | SmallMoleculeDrug |
| ENSG00000167552 | TUBA1A | DB07574 | 2-MERCAPTO-N-[1,2,3,10-TETRAMETHOXY-9-OXO-5,6,7,9-TETRAHYDRO-BENZO[A]HEPTALEN-7-YL]ACETAMIDE | SmallMoleculeDrug |
| ENSG00000167552 | TUBA1A | DB11638 | Artenimol | SmallMoleculeDrug |
| ENSG00000167552 | TUBA1A | DB12695 | Phenethyl Isothiocyanate | SmallMoleculeDrug |
| ENSG00000167552 | TUBA1A | DB15534 | Colchiceine | SmallMoleculeDrug |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
| ENSG00000167552 | TUBA1A | DB00570 | Vinblastine | SmallMoleculeDrug | Treat Breast Cancer,Gestational Trophoblastic Disease,Hodgkin Lymphoma,Kaposi Sarcoma,Non-Hodgkin Lymphoma,Testicular Cancer |
Top |
Structure and expression level for TUBA1A |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| TUBA1A | 8.89e+03 | 1.12e+00 | 1.08e-01 | 1.03e+01 | 4.51e-25 | 2.93e-24 | KIRC |
| TUBA1A | 5.25e+03 | 1.16e+00 | 1.88e-01 | 6.15e+00 | 7.75e-10 | 8.51e-09 | THCA |
| TUBA1A | 8.00e+03 | -1.35e+00 | 1.80e-01 | -7.48e+00 | 7.35e-14 | 2.40e-13 | LUSC |
| TUBA1A | 6.55e+03 | -1.86e+00 | 4.30e-01 | -4.33e+00 | 1.48e-05 | 8.38e-05 | BLCA |
| TUBA1A | 2.91e+03 | -1.71e+00 | 2.29e-01 | -7.44e+00 | 9.80e-14 | 9.57e-13 | COAD |
| TUBA1A | 3.46e+03 | 2.17e+00 | 5.25e-01 | 4.14e+00 | 3.54e-05 | 1.75e-04 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| TUBA1A | 4.16e+03 | -1.12e+00 | 3.68e-01 | -3.03e+00 | 2.47e-03 | 5.01e-03 | KICH |
| TUBA1A | 3.52e+03 | -1.66e+00 | 3.58e-01 | -4.65e+00 | 3.28e-06 | 2.45e-05 | READ |
Top |
Sex-biased somatic mutation for TUBA1A |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for TUBA1A |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| STAD | cg14802310 | chr12:49188816 | CGI:chr12:49188313-49189098 | UTR,promoter,exon,gene body | 2.11e-01 | 3.61e-01 | 4.00e+00 | 6.32e-05 | 3.23e-04 | -1.50e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| HNSC | cg22064451 | chr12:49189713 | CGI:chr12:49188313-49189098 | promoter | 6.92e-01 | 8.34e-01 | -2.54e+00 | 1.10e-02 | 1.39e-02 | -1.42e-01 |
| LIHC | cg12441358 | chr12:49187890 | CGI:chr12:49188313-49189098 | promoter,gene body | 2.41e-01 | 1.09e-01 | 2.05e+00 | 4.03e-02 | 4.14e-02 | 1.32e-01 |
| LIHC | cg14802310 | chr12:49188816 | CGI:chr12:49188313-49189098 | UTR,promoter,exon,gene body | 4.65e-01 | 1.99e-01 | 2.60e+00 | 9.35e-03 | 1.15e-02 | 2.66e-01 |
| LIHC | cg15367082 | chr12:49189260 | CGI:chr12:49188313-49189098 | UTR,promoter,exon,gene body | 2.36e-01 | 1.15e-01 | 2.03e+00 | 4.28e-02 | 4.36e-02 | 1.21e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg10481202 | chr12:49187489 | CGI:chr12:49188313-49189098 | promoter,gene body | 4.44e-01 | 2.06e-01 | 8.44e+00 | 3.17e-17 | 1.37e-16 | 2.38e-01 |
| LUAD | cg10481202 | chr12:49187489 | CGI:chr12:49188313-49189098 | promoter,gene body | 6.34e-01 | 4.33e-01 | 2.13e+00 | 3.34e-02 | 3.73e-02 | 2.01e-01 |
Top |
Exon skipping events with PSI in TCGA for TUBA1A |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for TUBA1A |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for TUBA1A |
| TFs related to TUBA1A. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| SARC | KLF10 | TUBA1A | 3.02e+00 | 2.07e-03 | 3.94e+00 | 9.82e-01 | Female-biased |
| SARC | PATZ1 | TUBA1A | 3.15e+00 | 1.83e-03 | 4.10e+00 | 9.86e-01 | Female-biased |
| SARC | ZNF141 | TUBA1A | 3.38e+00 | 1.69e-03 | 4.35e+00 | 9.90e-01 | Female-biased |
| SARC | ZNF267 | TUBA1A | 3.24e+00 | 4.96e-03 | 4.00e+00 | 9.80e-01 | Female-biased |
| SARC | ZNF28 | TUBA1A | 3.36e+00 | 2.03e-03 | 4.29e+00 | 9.89e-01 | Female-biased |
| SARC | ZNF30 | TUBA1A | 3.13e+00 | 3.16e-03 | 3.98e+00 | 9.82e-01 | Female-biased |
| SARC | ZNF304 | TUBA1A | 3.17e+00 | 3.55e-03 | 3.99e+00 | 9.82e-01 | Female-biased |
| SARC | ZNF320 | TUBA1A | 3.04e+00 | 1.77e-03 | 3.99e+00 | 9.84e-01 | Female-biased |
| SARC | ZNF460 | TUBA1A | 3.60e+00 | 4.80e-03 | 4.38e+00 | 9.88e-01 | Female-biased |
| SARC | ZNF566 | TUBA1A | 3.20e+00 | 2.94e-03 | 4.06e+00 | 9.84e-01 | Female-biased |
| SARC | ZNF611 | TUBA1A | 3.36e+00 | 2.14e-03 | 4.28e+00 | 9.89e-01 | Female-biased |
| SARC | ZNF682 | TUBA1A | 3.16e+00 | 1.30e-03 | 4.17e+00 | 9.88e-01 | Female-biased |
| SARC | ZNF740 | TUBA1A | 3.21e+00 | 3.79e-03 | 4.02e+00 | 9.82e-01 | Female-biased |
| SARC | ZNF816 | TUBA1A | 3.22e+00 | 2.39e-03 | 4.12e+00 | 9.86e-01 | Female-biased |
| SARC | ZSCAN22 | TUBA1A | 3.30e+00 | 5.35e-03 | 4.05e+00 | 9.81e-01 | Female-biased |
| TUBA1A related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for TUBA1A |
| RBPs related to ES in TUBA1A. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| UVM | MBNL1 | exon_skip_91899 | 9.94e+00 | 1.10e-02 | 1.02e+01 | 9.87e-01 | Female-biased |
| THYM | MBNL1 | exon_skip_91899 | 1.05e+01 | 9.93e-01 | 1.01e+01 | 6.15e-03 | Male-biased |
| COAD | MBNL1 | exon_skip_91899 | 1.04e+01 | 9.92e-01 | 1.01e+01 | 6.72e-03 | Male-biased |
| DLBC | MBNL1 | exon_skip_91899 | 9.99e+00 | 3.70e-03 | 1.04e+01 | 9.95e-01 | Female-biased |
| ESCA | MBNL1 | exon_skip_91899 | 9.85e+00 | 7.81e-03 | 1.03e+01 | 9.91e-01 | Female-biased |
| PAAD | MBNL1 | exon_skip_91899 | 1.00e+01 | 3.32e-03 | 1.04e+01 | 9.95e-01 | Female-biased |
| TUBA1A related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
| ENSG00000167552 | MIR100HG,hsa-mir-424,TUBA1A | Male-specific ceRNA | TCGA-THCA |
| ENSG00000167552 | SNHG12,hsa-mir-424,TUBA1A | Male-specific ceRNA | TCGA-THCA |
| ENSG00000167552 | BASP1-AS1,hsa-mir-424,TUBA1A | Male-specific ceRNA | TCGA-THCA |
| ENSG00000167552 | ACTN1-AS1,hsa-mir-424,TUBA1A | Male-specific ceRNA | TCGA-THCA |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs10506311 | chr12:52765488:C:T | - | 0.136732586517479 | 0.04234728288096 | STAD | Female-baised eQTL |
| rs73098468 | chr12:52765615:A:C | - | 0.136732586517479 | 0.04234728288096 | STAD | Female-baised eQTL |
| rs1521348 | chr12:52755399:G:A | - | 0.131609619253213 | 0.0439886428826117 | STAD | Female-baised eQTL |
| rs17117840 | chr12:52667698:A:G | - | 0.0771612030912313 | 0.00415234560315017 | LGG | Female-baised eQTL |
| rs1402588 | chr12:52673021:C:A | - | 0.0735588676517342 | 0.00605808682171297 | LGG | Female-baised eQTL |
| rs17117940 | chr12:52675930:C:T | - | 0.0731950868878244 | 0.00643305257137347 | LGG | Female-baised eQTL |
| rs12425650 | chr12:52679127:A:G | - | 0.0731950868878244 | 0.00643305257137347 | LGG | Female-baised eQTL |
| rs73094649 | chr12:52681576:G:T | - | 0.0717243090298283 | 0.0100440675210306 | LGG | Female-baised eQTL |
| rs3759192 | chr12:52682348:C:T | - | 0.0717243090298283 | 0.0100440675210306 | LGG | Female-baised eQTL |
| rs17118001 | chr12:52684251:C:T | - | 0.0717243090298283 | 0.0100440675210306 | LGG | Female-baised eQTL |
| rs55755326 | chr12:52685913:G:T | - | 0.0717243090298283 | 0.0100440675210306 | LGG | Female-baised eQTL |
| rs17118028 | chr12:52686184:G:A | - | 0.0717243090298283 | 0.0100440675210306 | LGG | Female-baised eQTL |
| rs17118035 | chr12:52686799:C:T | - | 0.0721882628463467 | 0.0105751821341557 | LGG | Female-baised eQTL |
| rs73094663 | chr12:52687985:A:T | - | 0.071079747596689 | 0.0134918376765057 | LGG | Female-baised eQTL |
| rs73094664 | chr12:52688165:C:G | - | 0.071079747596689 | 0.0134918376765057 | LGG | Female-baised eQTL |
| rs56246545 | chr12:52689416:A:G | - | 0.071079747596689 | 0.0134918376765057 | LGG | Female-baised eQTL |
| rs73094666 | chr12:52689582:G:A | - | 0.071079747596689 | 0.0134918376765057 | LGG | Female-baised eQTL |
| rs61926689 | chr12:42735006:G:A | - | 0.0846136527406881 | 0.0246222031945464 | LGG | Female-baised eQTL |
| rs10506217 | chr12:42737406:T:C | - | 0.0811200121546797 | 0.03468821452578 | LGG | Female-baised eQTL |
| rs149260903 | chr12:42897635:C:T | - | 0.10295063881778 | 0.0350854289029761 | LGG | Female-baised eQTL |
| rs144492338 | chr12:42897645:G:C | - | 0.10295063881778 | 0.0350854289029761 | LGG | Female-baised eQTL |
| rs870114 | chr12:42757501:C:T | - | 0.0786672277399059 | 0.0377241124179731 | LGG | Female-baised eQTL |
| rs61926683 | chr12:42731613:A:G | - | 0.0802233700492092 | 0.0399656328676325 | LGG | Female-baised eQTL |
| rs1914488 | chr12:42732119:A:C | - | 0.0802233700492092 | 0.0399656328676325 | LGG | Female-baised eQTL |
| rs2407108 | chr12:42732508:G:A | - | 0.0802233700492092 | 0.0399656328676325 | LGG | Female-baised eQTL |
| rs7977672 | chr12:42744243:C:T | - | 0.0728704085854265 | 0.0469094810298927 | LGG | Female-baised eQTL |
| rs55724981 | chr12:52685408:C:A | - | 0.0624217882429742 | 0.0498553689387839 | LGG | Female-baised eQTL |
| rs11613879 | chr12:48083794:C:T | - | 0.145241409781221 | 0.000402081153118323 | BLCA | Female-baised eQTL |
| rs80130819 | chr12:48025835:A:C | - | 0.144712618776176 | 0.000431890295758149 | BLCA | Female-baised eQTL |
| rs78239819 | chr12:48018767:C:T | - | 0.13616519127203 | 0.00112239485507683 | BLCA | Female-baised eQTL |
| rs17122571 | chr12:48027251:A:G | - | 0.134050966700529 | 0.00153665085276757 | BLCA | Female-baised eQTL |
| rs9651980 | chr12:48010853:C:T | - | -0.123935537711275 | 0.00299612446694821 | BLCA | Female-baised eQTL |
| rs11170132 | chr12:52459440:C:G | - | -0.0435321550446166 | 0.0465760516221502 | LUAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs58801386 | chr12:56912440:A:C | - | 0.175804629145247 | 0.0427604282009468 | GBM | Male-baised eQTL |
| rs11182288 | chr12:43825050:C:A | - | 0.0462921216596312 | 0.0388688401479922 | LIHC | Male-baised eQTL |
| rs11171568 | chr12:39273839:A:G | - | 0.115071656520221 | 0.0112959776275157 | STAD | Male-baised eQTL |
| rs11171662 | chr12:39287193:C:T | - | 0.112689732710791 | 0.0143273688723967 | STAD | Male-baised eQTL |
| rs11171666 | chr12:39289251:G:C | - | 0.112689732710791 | 0.0143273688723967 | STAD | Male-baised eQTL |
| rs11171669 | chr12:39291188:T:A | - | 0.112689732710791 | 0.0143273688723967 | STAD | Male-baised eQTL |
| rs76968732 | chr12:39543803:G:C | - | 0.113444957024127 | 0.0216259508065501 | STAD | Male-baised eQTL |
| rs78247220 | chr12:39550501:A:G | - | 0.113444957024127 | 0.0216259508065501 | STAD | Male-baised eQTL |
| rs11172566 | chr12:39553523:T:C | - | 0.113444957024127 | 0.0216259508065501 | STAD | Male-baised eQTL |
| rs11543371 | chr12:39557251:C:T | - | 0.113444957024127 | 0.0216259508065501 | STAD | Male-baised eQTL |
| rs11172603 | chr12:39559309:G:A | - | 0.11332888072778 | 0.0219862660141494 | STAD | Male-baised eQTL |
| rs7303111 | chr12:51890490:G:A | - | 0.0483644255968335 | 0.0439166608322441 | BLCA | Male-baised eQTL |
| rs7303030 | chr12:51890699:A:G | - | 0.0484010604768252 | 0.0441197712439771 | BLCA | Male-baised eQTL |
| rs11836228 | chr12:57690561:G:C | - | -0.103788291881065 | 0.0437719334530695 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000167552 |
| CpG Site: cg10481202 | |
| Position to Gene: gene,promoter | |
| Male Effect: - | |
| Female Effect: -0.370225508040304 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg10481202 | chr12:49187489 | gene,promoter | -0.370225508040304 | 2.69545870223523e-06 | -0.36759437430884007 | 1.7615130901492901e-09 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of TUBA1A |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000167552 | TUBA1A | C0019193 | Hepatitis, Toxic | 1 | CTD_human |
| ENSG00000167552 | TUBA1A | C0151744 | Myocardial Ischemia | 1 | CTD_human |
| ENSG00000167552 | TUBA1A | C0860207 | Drug-Induced Liver Disease | 1 | CTD_human |
| ENSG00000167552 | TUBA1A | C1262760 | Hepatitis, Drug-Induced | 1 | CTD_human |
| ENSG00000167552 | TUBA1A | C1969029 | Lissencephaly 3 | 1 | CTD_human |
| ENSG00000167552 | TUBA1A | C3658290 | Drug-Induced Acute Liver Injury | 1 | CTD_human |
| ENSG00000167552 | TUBA1A | C4277682 | Chemical and Drug Induced Liver Injury | 1 | CTD_human |
| ENSG00000167552 | TUBA1A | C4279912 | Chemically-Induced Liver Toxicity | 1 | CTD_human |
